Axon seeks global partner after positive Phase 2 data for Alzheimer’s vaccine

pharmafile | September 10, 2019 | News story | Manufacturing and Production, Sales and Marketing Alzheimer's, Alzheimers, Axon 

Axon Neuroscience has announced data from its Phase 2 trial ADAMANT for the first-in-class vaccine AADvac1 to slow the progression of Alzheimer’s disease.

Although the primary objective of the trial was safety, the trial data indicated a statistically significant improvement in a biomarker associated with the initial onset of Alzheimer’s – that being neuronal loss measured by Neurofilament Light Chain (NfL) in the blood. The data in this biomarker ultimately means that AADvac1 slows the progression of neurodegenerative processes to levels typically seen in healthy individuals.

The trial, involving 196 patients in eight European countries over 24 months, also managed to produce a highly effective immune response with 98.2% of patients generating antibodies against pathological tau.

Advertisement

Michal Fresser, CEO at Axon Neuroscience, said: “Today’s results mark an important milestone for Axon and for the entire population of the world that suffers from this devastating disease.

“These results strongly reveal a disease-modifying effect on the disease [and] underpin our confidence to taken the next steps in bringing a life-changing treatment to patients as soon as possible.”

The news comes after multiples failures in the Alzheimer’s department from Eli Lilly, Biogen, and MSD as researchers are being forced to rethink the amyloid hypothesis and focus on other areas such as targeting nuerofibrally tangles called ‘tau’.

Nik Kiran

Related Content

brain-770044_960_720

Lilly’s drug for early Alzheimer’s shows promising results

Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …

Eisai presents latest findings for lecanemab at Alzheimer’s Association International Conference (AAIC)

Clarity AD open-label extension (OLE) data show: three years of continuous lecanemab treatment reduced clinical …

Eli Lilly’s Kisunla approved by FDA for Alzheimer’s treatment

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla …

The Gateway to Local Adoption Series

Latest content